• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过钇-87成像分析钇-90的生物分布:一项理论可行性分析。

Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis.

作者信息

Sgouros G

机构信息

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

出版信息

Med Phys. 1998 Aug;25(8):1487-90. doi: 10.1118/1.598323.

DOI:10.1118/1.598323
PMID:9725138
Abstract

Yttrium-90 is widely used in radioimmunotherapy but does not emit photons for imaging. Indium-111, a chemically similar atom has been used instead as a tracer for the distribution of 90Y-labeled antibodies. Recent advances in gamma camera technology have made it possible to image at energies higher than 364 keV. This work provides a theoretical analysis of the feasibility of using 87Y (485 keV, 92.2% yield) as a tracer for in vivo imaging of 90Y-labeled antibodies. Yttrium-87 may be produced by the 87Sr(p,n)87Y reaction in a cyclotron and has a 3.3 day half-life. This reaction also yields a metastable state of 87Y (87mY). Yttrium-87, itself decays to a metastable state of 87Sr (87mSr). The level of these contaminants and their anticipated impact on the utility of 87Y as a tracer for 90Y are examined theoretically. Dosimetry is performed to assess the absorbed dose associated with using 87Y. A 100 h delay following the end of bombardment of an isotopically enriched 87Sr target reduces the activity of the metastable state of 87Y in the product by 10- to 15-fold, with greater delays resulting in a further reduction. A rapid equilibration between 87Y and its daughter, 87mSr, is expected, in vivo. Although strontium is known to concentrate in bone, the electron emissions of 87mSr are short range, thereby making possible biologic effects highly position dependent; the photon emissions allow for independent imaging which may be used to perform dosimetry and thereby directly assess potential toxicity. 87Y merits further consideration as an imaging tracer for 90Y.

摘要

钇-90广泛应用于放射免疫治疗,但不发射用于成像的光子。铟-111是一种化学性质相似的原子,已被用作钇-90标记抗体分布的示踪剂。γ相机技术的最新进展使得在高于364keV的能量下成像成为可能。这项工作对使用钇-87(485keV,产率92.2%)作为钇-90标记抗体体内成像示踪剂的可行性进行了理论分析。钇-87可通过回旋加速器中的87Sr(p,n)87Y反应产生,半衰期为3.3天。该反应还会产生钇-87的亚稳态(87mY)。钇-87本身会衰变为锶-87的亚稳态(87mSr)。从理论上研究了这些污染物的水平及其对钇-87作为钇-90示踪剂效用的预期影响。进行剂量测定以评估与使用钇-87相关的吸收剂量。对同位素富集的87Sr靶进行轰击结束后延迟100小时,可使产物中钇-87亚稳态的活度降低10至15倍,延迟时间越长,活度进一步降低。预计在体内钇-87与其子体87mSr之间会迅速达到平衡。虽然已知锶会在骨骼中富集,但87mSr的电子发射射程短,因此生物效应高度依赖位置;光子发射可用于独立成像,可用于进行剂量测定,从而直接评估潜在毒性。钇-87作为钇-90的成像示踪剂值得进一步考虑。

相似文献

1
Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis.通过钇-87成像分析钇-90的生物分布:一项理论可行性分析。
Med Phys. 1998 Aug;25(8):1487-90. doi: 10.1118/1.598323.
2
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.实体瘤放射免疫治疗中高传能线密度(LET)的α发射体与低LET的β发射体对比:人结肠癌模型中213Bi标记与90Y标记的CO17-1A Fab'片段的治疗效果及剂量限制毒性
Cancer Res. 1999 Jun 1;59(11):2635-43.
3
[Scintigraphic use of 87Y during 90Y therapy of bone metastases].[骨转移瘤90Y治疗期间87Y的闪烁成像应用]
Nuklearmedizin. 1992 Mar;31(2):53-6.
4
Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.采用预靶向NR-LU-10/链霉亲和素对90Y-DOTA-生物素的辐射吸收剂量估计
Cancer Biother Radiopharm. 1999 Oct;14(5):381-95. doi: 10.1089/cbr.1999.14.381.
5
Yttrium-87 for in vivo imaging.用于体内成像的钇-87
Int J Rad Appl Instrum B. 1991;18(2):261-2. doi: 10.1016/0883-2897(91)90089-4.
6
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.钇-90/铟-111-DOTA-肽嵌合体L6:不可治愈乳腺癌患者的药代动力学、剂量学及初步结果
Anticancer Res. 1997 May-Jun;17(3B):1735-44.
7
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.90Y-多胺基多羧基大环配体-人源化抗CD19单克隆抗体:一种用于非霍奇金淋巴瘤放射免疫治疗的药物。
J Nucl Med. 2003 Jan;44(1):77-84.
8
Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.铟 - 111和钇 - 90标记的单克隆抗体CC49的个体化剂量测定
J Nucl Med. 1997 Apr;38(4):512-6.
9
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.90Y-伊布妥昔单抗放射性免疫疗法治疗复发或难治性非霍奇金淋巴瘤的辐射剂量学结果及安全性相关性:来自4项临床试验的综合数据
J Nucl Med. 2003 Mar;44(3):465-74.
10
Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
Clin Cancer Res. 1998 Jul;4(7):1679-88.

引用本文的文献

1
Targeted Radionuclide Therapy of Human Tumors.人类肿瘤的靶向放射性核素治疗
Int J Mol Sci. 2015 Dec 28;17(1):33. doi: 10.3390/ijms17010033.
2
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?内照射治疗用镱[90Y]标记放射性药物的剂量学:用[86Y]还是[90Y]成像?
Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S57-68. doi: 10.1007/s00259-011-1771-7. Epub 2011 Mar 11.
3
Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.利用 SIR-Spheres 进行 90Y TOF PET 基于剂量学在肝转移治疗中的可行性。
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1654-62. doi: 10.1007/s00259-010-1470-9. Epub 2010 Apr 27.